Business Wire

CA-PATIENT-SAFETY

10.11.2021 14:02:09 CET | Business Wire | Press release

Share
Seven Healthcare Industry "High Reliability Organization Champions" Recognized by Patient Safety Movement Foundation

Medical errors claim the lives of nearly three million individuals across the globe every year. In any other high-risk industry, like aviation and nuclear power, these numbers would not be acceptable. Yet, the healthcare industry has continued to allow these events to occur—putting patients and staff at risk. The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, believes that to reach this goal healthcare organizations that provide care to patients need to commit to operating as highly reliable organizations (HROs) to reduce preventable medical harm. To support this, PSMF launched its new HRO Champion Program and is excited to recognize the first seven healthcare organizations that have committed to this effort. These HRO Champions include: Kaiser Permanente Northern California, Parrish Medical Center (Titusville, Fla.), Hospital Puebla (Puebla, Mexico), Hospitales Star Medica (Mexico City, Mexico), Hospital Materno Infantil Irapuato (Irapuato, Mexico), Hospital de Especialidades Pediatrico Leon (San Jose del Potrero, Mexico) and Hospital Español (Granada, Mexico).

“The pandemic exposed gaps in the global healthcare system, which forced us to examine the processes in place and identify ways we can prioritize patient safety,” stated Dr. Mike Ramsay, CEO of PSMF. “We are proud to recognize and unite healthcare systems that share this mission and provide them resources to help improve their processes and eliminate preventable harm in their organizations.”

The new HRO Champions program puts an emphasis on data transparency, as this is a critical component to achieving zero harm and improving patient safety. To participate, hospitals and healthcare organizations commit to sharing their adverse event and near-miss data, once annually, to measure the impact of improvements in the network over time. Not only does transparency hold health systems accountable, but it also makes it easier for patients to access safety information to make informed healthcare decisions.

“We are honored to have been designated as HRO Champions by the Patient Safety Movement Foundation, in which we have found a valuable ally to continue improving our care processes,” stated Jose Testas Anton, vice president of Hospital Español. “At Hospital Español, we believe that being able to share and collaborate with other health systems and provide information related to patient safety outside the walls of our organization will help generate collaborative learning and promote patient safety around the world.”

“We are pleased to be recognized for our unwavering commitment to provide safe and reliable patient care and commend our staff for being strong advocates for and partnering with their patients to prevent unnecessary harm,” said Robin Betts, vice president of safety, quality and regulatory services for Kaiser Permanente Northern California. “Our hospitals are among the country’s highest performing for minimizing patient injuries, medication errors and infections. We have processes in place, which closely align with the Patient Safety Movement Foundation to highlight potential safety issues for our care teams who focus every day on protecting the health of their patients, keeping them safe from harm and providing the highest quality care.”

By committing to zero harm, healthcare organizations are eligible for many different benefits, including free coaching, workshops, publicity and other tools. HRO Champions are announced every month and can submit data any time throughout the year to be eligible. Learn more about how to become a HRO Champion: https://patientsafetymovement.org/take-action/organizational-action/going-above-and-beyond/hro-champions/

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye